January 8, 2018 / 5:45 AM / 13 days ago

BRIEF-Novo Nordisk has proposed to buy Ablynx for up to 30.50 euros per share in cash

Jan 8 (Reuters) - Novo Nordisk:

* HAS PROPOSED TO BUY ABLYNX FOR UP TO EUR 30.50 PER SHARE IN CASH, CONSISTING OF EUR 28.00 UPFRONT AND EUR 2.50 IN CONTINGENT VALUE RIGHTS​

* ‍PROPOSAL IMPLIES A TOTAL EQUITY VALUATION OF APPROXIMATELY EUR 2.6 BILLION FOR ABLYNX​

* PROPOSAL IS SECOND PROPOSAL THAT CO HAS MADE TO ABLYNX‘S BOARD AND REPRESENTS UP TO APPROXIMATELY A 14% INCREASE OVER FIRST PROPOSAL​

* CO “REGRETS” THAT BOARD OF ABLYNX HAS SO FAR DECLINED TO ENGAGE IN ANY DISCUSSIONS, DESPITE PROPOSALS WHICH HAVE BEEN PUT FORWARD​

* PROPOSAL ALSO CONSISTS OF ONE CONTINGENT VALUE RIGHT WITH TOTAL POTENTIAL CASH PAYMENTS OVER TIME OF UP TO EUR 2.50 PER SHARE​ Further company coverage:,

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below